Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TScan Therapeutics Inc TCRX

Healthcare Biotechnology
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual... see more

Recent & Breaking News (NDAQ:TCRX)

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA(TM) Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire 12 days ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

GlobeNewswire December 5, 2024

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA(TM) Phase 1 Trial and Heme Development Strategy

GlobeNewswire December 2, 2024

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2024

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA(TM) Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire November 5, 2024

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

GlobeNewswire October 4, 2024

TScan Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 29, 2024

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2024

TScan Therapeutics Announces Updates to its Board of Directors

GlobeNewswire June 14, 2024

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

GlobeNewswire May 29, 2024

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 13, 2024

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

GlobeNewswire May 9, 2024

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

GlobeNewswire April 24, 2024

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire April 24, 2024

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

GlobeNewswire April 22, 2024

TScan Therapeutics Announces Closing of Upsized Public Offering

GlobeNewswire April 19, 2024

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

GlobeNewswire April 17, 2024

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

GlobeNewswire April 16, 2024

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

GlobeNewswire April 16, 2024